• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

OCUL registers for $40m stock sale

November 30, 2016 By Sarah Faulkner

OCUL registers for $40m stock saleOcular Therapeutix (NSDQ:OCUL) is looking to raise $40 million through a public stock offering, according to a prospectus filed with the federal Securities & Exchange Commission this week.

The Bedford, Mass.-based company said it inked a controlled equity offering sales agreement with Cantor Fitzgerald & Co., and agreed to pay Cantor Fitzgerald commissions of up to 3% of the process from the sales of the shares for it services.

Earlier this month, the OCUL shares soared following positive phase III clinical data for its post-surgical ocular pain reliever, Dextenza. The hydrogel plug is designed to deliver a sustained dose of dexamethasone for weeks following ophthalmic surgery. In the clinical study, which enrolled nearly 440 patients at 21 states across the U.S., Dextenza reduced both pain and inflammation better than the placebo treatment.

The trial met its 2 primary efficacy endpoints for inflammation and pain, achieving statistically significant differences between the treatment arm and the placebo for the absence of inflammatory cells and pain.

Ocular also said this month that it will re-submit its new drug application to the FDA for Dextenza, in the hopes of winning approval in the beginning of 2017.

In July, the FDA denied approval for Ocular’s hydrogel plug, citing concerns related to “deficiencies in manufacturing process and controls” which were identified during a pre-NDA approval inspection of its manufacturing facility.

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Implants, Optical/Ophthalmic, Surgical Tagged With: Ocular Therapeutix

IN CASE YOU MISSED IT

  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS